重症COVID-19患者常见诊断自身抗原的自身抗体未升高
该研究检测了重症与中度COVID-19患者及对照血清中23种常见自身免疫诊断标志物的IgG自身抗体水平。结果显示重症COVID-19患者未出现任何所测标志物自身抗体的显著升高。未来研究应考虑更长时间点的样本采集以评估感染后自身抗体反应。
要点
- 重症COVID-19患者未显示常见自身诊断抗体显著升高
- 研究采用MSD U-PLEX电化学发光法检测23种自身抗原
- 建议未来研究延长样本采集时间点以评估自身抗体反应
核心结论
- 重症COVID-19患者中未观察到针对所测23种常见自身免疫诊断标志物的自身抗体显著升高。
研究设计与样本
- 研究纳入18例ICU COVID-19阳性患者(3至6个时间点)、18例ICU COVID-19阴性患者(ICU第1和3天)、21例普通病房COVID-19阳性患者(住院第1和3天)及59例健康未感染对照(来自两个队列)。
主要发现
- 采用MSD® U-PLEX电化学发光技术检测血清中针对23种自身抗原的IgG自身抗体水平,各组间比较未见重症COVID-19患者任何所测标志物自身抗体显著升高。
临床怎么用
- 对重症COVID-19患者,常规自身免疫诊断抗体检测结果不应轻易归因于SARS-CoV-2感染导致的自身抗体升高。
局限性
- 样本采集时间点有限(急性至感染后26个ICU日),未来研究应考虑更长时间点的样本采集以评估感染后自身抗体反应的可能发展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19) presents occasionally with an aberrant autoinflammatory response, including the presence of elevated circulating autoantibodies in some individuals. Whether the development of autoantibodies against self-antigens affects COVID-19 outcomes remains unclear. To better understand the prognostic role of autoantibodies in COVID-19, we quantified autoantibodies against 23 markers that are used for diagnosis of autoimmune disease. To this end, we used serum samples from patients with severe [intensive care unit (ICU)] and moderate (ward) COVID-19, across two to six consecutive time points, and compared autoantibody levels to uninfected healthy and ICU controls. METHODS: Acute and post-acute serum (from 1 to 26 ICU days) was collected from 18 ICU COVID-19-positive patients at three to six time points; 18 ICU COVID-19-negative patients (sampled on ICU day 1 and 3); 21 ward COVID-19-positive patients (sampled on hospital day 1 and 3); and from 59 healthy uninfected controls deriving from two cohorts. Levels of IgG autoantibodies against 23 autoantigens, commonly used for autoimmune disease diagnosis, were measured in serum samples using MSD® U-PLEX electrochemiluminescence technology (MSD division Meso Scale Discovery®), and results were compared between groups. RESULTS: There were no significant elevations of autoantibodies for any of the markers tested in patients with severe COVID-19. CONCLUSIONS: Sample collections at longer time points should be considered in future studies, for assessing the possible development of autoantibody responses following infection with SARS-CoV-2.
引用
- Ulndreaj A, Wang M, Misaghian S, et al. Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens. Clin Chem Lab Med. 2022. PMID: 35475723. doi:10.1515/cclm-2022-0239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。